Systemic Lupus Erythematosus  >>  INV103  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
INV103 / Invion
NCT01838694: Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE.

Completed
1/2
30
US
Ala-Cpn10, Placebo
Invion, Inc.
Lupus Erythematosus, Systemic
08/15
08/15

Download Options